Lyrica® CR (pregabalin) – New formulation approval
October 12, 2017 – Pfizer announced the FDA approval of Lyrica CR (pregabalin) extended-release tablets, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).
Download PDF
